Ozempic Vision-Loss Lawsuits Move Forward in Federal Court

The gastrointestinal side effects of Ozempic and the other GLP-1 drugs have been in the news for two years. Gastroparesis, ileus, and intestinal obstruction have produced thousands of personal injury claims, and the federal multidistrict litigation focused on those injuries (MDL 3094, before Judge Karen Marston in the Eastern District of Pennsylvania) had 3,636 pending cases as of May 2026. What has received far less public attention, and what every current and former Ozempic patient should understand, is a separate and far more devastating injury that has been emerging in the medical literature: sudden, often permanent vision loss from a condition called non-arteritic anterior ischemic optic neuropathy, or NAION.

NAION is a stroke of the optic nerve. The small blood vessels supplying the front portion of the nerve become blocked or otherwise lose adequate blood flow, and the affected portion of the nerve dies. The injury is usually painless, frequently noticed first thing in the morning, and most patients describe it as a sudden, irreversible loss of vision in one eye, sometimes complete and sometimes partial. The condition has long been associated with cardiovascular risk factors, sleep apnea, and certain medications, but the recent finding that connects NAION to GLP-1 drugs has changed the medical conversation considerably.

In July 2024, JAMA Ophthalmology published a study by researchers at Mass Eye and Ear that examined the records of more than 16,000 patients. The study found that diabetic patients prescribed semaglutide (the active ingredient in Ozempic and Wegovy) had approximately four times the risk of developing NAION compared to those prescribed other diabetes medications. For overweight or obese patients without diabetes, the elevated risk was even higher. Subsequent research has refined those numbers, with some analyses suggesting the relative risk for NAION is as much as seven times higher in patients on GLP-1 receptor agonists than in matched controls. The studies do not prove causation in any individual patient, but they have established a strong enough signal that the U.S. Judicial Panel on Multidistrict Litigation created a separate federal MDL specifically for these claims.

That new MDL, captioned In re: GLP-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation and docketed as MDL 3163, was assigned to Judge Marston in early 2026. The panel declined Eli Lilly's request to fold the NAION cases into the existing gastrointestinal MDL, instead creating a standalone docket. Plaintiffs allege that Novo Nordisk (the manufacturer of Ozempic, Wegovy, and Rybelsus) and Eli Lilly (the manufacturer of Mounjaro, Zepbound, and Trulicity) knew or should have known of the vision-loss risk and failed to warn patients and physicians. As of mid-2026, the NAION docket is being actively populated, and the first bellwether trials are tentatively scheduled for late 2026 and early 2027, though those dates often slip.

Patients who may have a claim share a recognizable profile. They were prescribed Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Victoza, or Saxenda. They experienced a sudden loss of vision in one eye, typically while still on the medication or shortly after. They received a diagnosis of NAION from an ophthalmologist or neuro-ophthalmologist, often following a workup that included visual field testing, optical coherence tomography (OCT) imaging, and ruling out giant cell arteritis. The vision loss has, in most cases, been permanent, with no meaningful return of acuity in the affected eye, and in a smaller subset of patients, the second eye has subsequently been affected as well.

The statute of limitations in California for product-liability claims is generally two years from the date of injury, but the calculation is more complicated in pharmaceutical cases. The discovery rule typically tolls the limitations period until the patient knew, or reasonably should have known, both that they were injured and that the injury may have been caused by the medication. For NAION, that often means the clock starts not on the day vision was lost, but on the day a physician first connected the vision loss to the GLP-1 drug, which in many cases was months or even years later. Patients who lost vision in 2023, 2024, or 2025 should not assume their claims are time-barred. A careful review of the medical history is required.

For patients still taking these medications, none of this is a recommendation to stop. NAION is rare in absolute terms, even with the elevated relative risk, and the cardiovascular and metabolic benefits of GLP-1 therapy for the right patient can be substantial. The decision to continue, modify, or discontinue therapy belongs to the patient and the prescribing physician, and abruptly stopping any prescribed medication can produce its own problems. What patients should do, however, is report any sudden vision changes immediately, both to an ophthalmologist and to the prescribing physician, and preserve every record of the prescription, the dosage, the dates of administration, and any communications with the manufacturer or the pharmacy.

The Ozempic vision-loss litigation is still in its early phases, but it has the structural markings of a major mass tort. The MDL is in place, the science is developing, the patient population is enormous (more than fifteen percent of American adults have used a GLP-1 drug at some point), and the injury, when it occurs, is catastrophic and permanent. For anyone who has been told that their sudden vision loss might be related to a diabetes or weight-loss medication, the right next step is a conversation with a product-liability attorney while the records are fresh and the relevant treating physicians are still available to testify.

CONTACT PHILLIPS & ASSOCIATES TODAY

If you or a loved one has been injured due to the negligence of a third party, contact Phillips & Associates at (818) 348-9515 for a free consultation today. You will immediately be put in touch with John Phillips or Patrick DiFilippo, who can help determine whether you have a case and advise you on the best course of action moving forward.